PHARMACY

Warner Chilcott sees gain

BY Allison Cerra

NEW YORK Warner Chilcott has “grade A” revenues for 2007.

Specialty pharmaceutical company said Friday it expects revenue in 2007 to hit the high end of its forecast.

The company previously forecast revenue between $870 million and $890 million. It also expects adjusted profit to range from $1.03 to $1.05 per share. This, the company said, excludes paying back and write-off of deferred loan costs related to debt.

Analysts polled by Thomson Financial expect full-year profit of $1.02 per share on revenue of $883.7 million.

The company estimated selling, general and administration expenses at $262 million to $271 million, with higher legal costs. Research and development expenses are expected to range from $54 million to $57 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Eisai announces new hires and appointments

BY Drew Buono

WOODCLIFF LAKE, N.J. Eisai Inc., the U.S. subsidiary of Eisai Co., today announced new hires and appointments within the company, which produces such drugs as the acid-reflux medication Aciphex and Aricept, which is used to treat mild, moderate and severe Alzheimer’s disease.

Sunitha Ramamurthy has joined Eisai Corporation of North America as compliance director of Research and Development. Christine Drobot has joined the company as counsel for Employment and Research and Development. Barbara Sudovar has joined Eisai Inc. as director of U.S. Market Research.

Steven Brown has been promoted to director of Marketing Finance and will be responsible for financial reporting and business planning of product line P&Ls. Prior to this promotion, Steven was associate director of Marketing Finance for two years and marketing finance manager on the Aricept brand for two years. Terry Paluga has been promoted to specialty district manager where she will oversee the Baltimore Specialty District.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Study shows Zocor could increase incidence of sleep disorders

BY Drew Buono

WHITEHOUSE STATION, N.J. A new study showed that patients on the cholesterol drug Zocor were three times as likely to suffer from insomnia than those who took another cholesterol drug Pravachol and those taking a placebo, according to Bloomberg.com.

Insomnia is listed as a possible side effect for all cholesterol-lowering drugs. Merck spokesman Ron Rogers said the company found no significant effects on sleep in its own insomnia studies comparing Zocor with pravastatin, the generic of Pravachol and a placebo. Nor did the company see sleep disruption as a side effect in two other studies testing the drug’s effectiveness in thousands of patients.

The National Institutes of Health, in Bethesda, Maryland, funded the study. Zocor was the world’s second-best-selling cholesterol pill, behind Pfizer’s Lipitor, before it lost patent protection in June 2006.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?